Alemtuzumab versus interferon beta-1a: implications for pathology and trial design

The Lancet Neurology

Volumn 8, Issue 1, 2009, Pages 26-28

  McFarland, Henry F ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON; MYELIN;

DEATH; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFLAMMATION; LETTER; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 57249084210     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(08)70280-1     Document Type: Letter

References (4)

1. Coles A.J., Compston D.A., Selmaj K.W., et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359 (2008) 1786-1801
2. Kremenchutzky M., Rice G.P., Baskerville J., Wingerchuk D.M., and Ebers G.C. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain 129 (2006) 584-594
3. Coles A.J., Wing M.G., Molyneux P., et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 46 (1999) 296-304
4. Ebers G.C., Heigenhauser L., Daumer M., Lederer C., and Noseworthy J.H. Disability as an outcome in MS clinical trials. Neurology 71 (2008) 624-631